Edition:
India

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

2.99USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$2.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
479,275
52-wk High
$5.66
52-wk Low
$2.69

Latest Key Developments (Source: Significant Developments)

Achillion Initiates Phase I First-In Study Of ACH-5228
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D.ACHILLION PHARMACEUTICALS INC - COMPANY EXPECTS TO REPORT INTERIM CLINICAL DATA FROM STUDY DURING SECOND HALF OF 2018.  Full Article

Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Achillion Pharmaceuticals Inc ::ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY.ACHILLION PHARMACEUTICALS INC - INITIATED BIOAVAILABILITY STUDY EVALUATING EXTENDED-RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.ACHILLION PHARMACEUTICALS INC - INITIATION OF BIOAVAILABILITY STUDY OF EXTENDED RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS.  Full Article

Achillion announces pricing of secondary offering of common stock
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces pricing of secondary offering of common stock.Says secondary public offering of 18.4 million common shares priced at $2.75per share.  Full Article

Achillion announces proposed secondary offering of common stock
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion announces proposed secondary offering of common stock.Achillion Pharmaceuticals Inc says ‍intends to offer for sale in an underwritten public offering 18.4 million shares of common stock of achillion​.Achillion Pharmaceuticals - existing stockholder of company, Johnson & Johnson Innovation-JJDC Inc will be making the offering of common stock.Achillion Pharmaceuticals Inc - ‍achillion will not sell any shares or receive any proceeds from offering​.  Full Article

Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Achillion Pharmaceuticals Inc :Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g.Achillion Pharmaceuticals Inc - ‍greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ach-4471​.Achillion Pharmaceuticals Inc - ‍improvement in complement alternative pathway biomarkers observed​.Achillion Pharmaceuticals Inc - ‍preliminary data from phase 2 trial suggest that ach-4471 may reverse ap hyperactivity in c3g​.Achillion Pharma- ‍preliminary data from phase 2 trial suggest ach-4471 may have potential to reverse AP hyperactivity resulting in improvement in proteinuria​.  Full Article

Achillion says ACH-4471 granted orphan drug designation by FDA
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Achillion Pharmaceuticals Inc :Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria.Achillion Pharma - ‍EMA committee for orphan medicinal products issued a positive opinion on ACH-4471 for orphan status in EU for treatment of PNH​.  Full Article

Achillion Q3 loss per share $0.14
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Achillion Pharmaceuticals Inc ::Achillion reports third quarter 2017 financial results and provides update on clinical programs.Q3 loss per share $0.14.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.  Full Article

Achillion Pharmaceuticals reports Q2 loss per share $0.14
Friday, 5 Aug 2016 

Achillion Pharmaceuticals Inc : Achillion reports second quarter 2016 financial results .Achillion Pharmaceuticals Inc qtrly loss per share $0.14.  Full Article

Achillion presents interim phase 1 results for ACH-4471
Friday, 10 Jun 2016 

Achillion says : Presents interim phase 1 results for ACH-4471, a novel orally-administered factor D inhibitor . Results indicate up to 100% inhibition of alternative-pathway activity in hemolysis and Wieslab assays after oral dosing of ACH-447 .Results support initiation of phase 1 trial during q2 and phase 2 studies for PNH and C3G by year-end 2016.  Full Article

BRIEF-Achillion Initiates Phase I First-In Study Of ACH-5228

* ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D